Mylan has two segments, "Generics" and "Specialty." The Generics Segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients ("API"). The Specialty Segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products.

The Company's chief operating decision maker evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct research and development expenses and direct selling, general and administrative expenses. Certain general and administrative and research and development expenses not allocated to the segments, as well as net charges for litigation settlements, impairment charges and other expenses not directly attributable to the segments, are reported in Corporate/Other. Additionally, amortization of intangible assets and other purchase accounting related items, as well as any other significant special items, are included in Corporate/Other. Items below the earnings from operations line on the Company's Condensed Consolidated Statements of Operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in the "Summary of Significant Accounting Policies" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2010. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Three Months Ended June 30, 2011
Total revenues
Third party	$	1,441,433	$	132,444	$	—		$	1,573,877
Intersegment		405		17,449		(17,854	)		—

Total	$	1,441,838	$	149,893	$	(17,854	)	$	1,573,877

Segment profitability	$	431,617	$	46,852	$	(197,998	)	$	280,471

	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Six Months Ended June 30, 2011
Total revenues
Third party	$	2,791,904	$	230,930	$	—		$	3,022,834
Intersegment		802		34,284		(35,086	)		—

Total	$	2,792,706	$	265,214	$	(35,086	)	$	3,022,834

Segment profitability	$	820,539	$	77,644	$	(406,038	)	$	492,145

	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Three Months Ended June 30, 2010
Total revenues
Third party	$	1,242,655	$	125,881	$	—		$	1,368,536
Intersegment		1,502		17,216		(18,718	)		—

Total	$	1,244,157	$	143,097	$	(18,718	)	$	1,368,536

Segment profitability	$	333,253	$	35,315	$	(173,982	)	$	194,586


	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Six Months Ended June 30, 2010
Total revenues
Third party	$	2,450,516	$	210,393	$	—		$	2,660,909
Intersegment		31,921		33,730		(65,651	)		—

Total	$	2,482,437	$	244,123	$	(65,651	)	$	2,660,909

Segment profitability	$	658,587	$	55,119	$	(320,615	)	$	393,091

⁽¹⁾

Includes certain corporate general and administrative and research and development expenses; net charges for litigation settlements; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges, if any; and other expenses not directly attributable to segments.